We aimed to evaluate the efficacy and toxicity profile of busulfan-fludarabine (Bu-Flu) compared with busulfan-cyclophosphamide (Bu-Cy) as a preparative regimen for patients undergoing allogeneic hematopoietic cell transplantation. We performed a systematic review and meta-analysis of all comparative trials, both randomized controlled trials (RCTs) and non-randomized. Our search yielded 15 trials recruiting 1830 patients. Four trials were RCTs and 11 were either one-arm intervention trials compared with historical controls or retrospective studies. There was a lower risk for non-relapse mortality (NRM) at 100 days in patients given Bu-Flu regimen compared with those given Bu-Cy regimen (relative risk (RR) 0.56; 95% confidence interval (CI) 0.34-0.92, 8 trials); however, there were no differences in all-cause mortality at 100 days (RR 0.85; 95% CI 0.56-1.30, 9 trials) and at the end of study (RR 0.81; 95% CI 0.64-1.02, 13 trials). The risks of sinusoidal obstruction syndrome (SOS) and microbiologically documented infections were lower in patients given Bu-Flu regimen (RR 0.34; 95% CI 0.19-0.62, 8 trials and RR 0.79; 95% CI 0.64-0.97, 2 trials, respectively); however, risk for SOS was no longer lower when performing sensitivity analysis according to RCTs. Engraftment kinetics, risk of grade 3-4 mucositis, GvHD, relapse and NRM at the end of the study were all similar between the two groups. We conclude that both regimens have similar efficacy profiles, whereas toxicity is lower with the Bu-Flu regimen. (2016) 51, 232-240; doi:10.1038/bmt.2015.238; published online 12 October 2015
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for a variety of hematological disorders. The therapeutic potential of allogeneic HCT relies on the GvL effect, which eradicates malignant cells by immunologic mechanisms; however, efficacy is hampered by significant regimen-related toxicities, which limit the broader application of this important modality. 1 The preparative regimen consisting of busulfan and cyclophosphamide (Bu-Cy) is considered as one of the classical myeloablative preparative regimens; however, it is associated with significant early and long-term toxicities, leading to a high rate of transplantation-associated mortality, mainly among elderly and medically infirm patients. 2 Fludarabine, a purine analog with anti-neoplastic and immunosuppressive activity, has a potentially less toxic profile while it maintains the immunosuppressive efficacy of cyclophosphamide. 3 Although early studies showed that a myeloablative regimen consisted of busulfan and fludarabine (Bu-Flu) was associated with fewer regimen-related toxicities, compared with the Bu-Cy regimen, the comparability of the Bu-Flu regimen is still a matter of debate.
We aimed to evaluate the efficacy and toxicity profiles of Bu-Flu compared with Bu-Cy as a preparative regimen before allogeneic HCT given to patients with hematological malignancies by performing a systematic review and meta-analysis of comparative trials.
METHODS

Data sources
We conducted a comprehensive search to identify both published and unpublished studies, with no restriction for language or study years. We included all comparative studies, both randomized controlled trials (RCTs) and non-randomized studies, in patients undergoing allogeneic HCT after myeloablative conditioning regimen with either Bu-Flu or Bu-Cy. 4 We crossed the terms 'busulfan' or 'busulfex' or 'Bu' with 'fludarabine' or 'Flu' and with 'allogeneic' and similar. We searched The Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library (Issue 4, 2014) . In PubMed search, we crossed the search strategy with the highly sensitive search for prospective trials. 5 When multiple reports were published from a single study, the publication that reported the longest period of follow-up was selected for inclusion. 
Study selection
We included RCTs, cohort studies, case-control or nested case-control studies. We defined myeloablative doses of busulfan according to the ASBMT working party recommendations and we excluded studies analyzing reduced intensity combinations of Bu-Flu. 4 Retrospective surveillance analyses performed based on The European Group for Blood and Marrow Transplantation or The International Bone Marrow Transplant Registry databases were not included in the analysis to avoid reanalyzing patients who had been already reported in other included studies.
Data extraction
Two reviewers (SB and OC) independently inspected each reference identified by the search and applied inclusion criteria. When relevant articles were identified, the full article was obtained and inspected independently by the above two reviewers and inclusion criteria were applied.
Outcomes
Primary outcomes were non-relapse mortality (NRM) at 100 days and allcause mortality (ACM) at the end of study. We chose these primary outcomes, based on the original rationale of utilizing Bu-Flu as a less toxic regimen with similar efficacy compared with the 'traditional' Bu-Cy regimen. When long-term follow-up was reported, mortality data at the longest available time point, but no longer than 5 years was used for analysis, as 5 years is a sufficient period of time to evaluate relapse-related mortality and regimen-related toxicities. 6 Secondary outcomes were time to neutrophil engraftment, primary and secondary graft failure, risk of grade 3-4 mucositis, sinusoidal obstruction syndrome (SOS)-defined as either overall SOS or grade 3-4 liver enzyme disturbance, microbiologically documented infection, overall and grade 3-4 acute GvHD, overall and extensive chronic GvHD, NRM at the end of study, relapse risk and ACM at 100 days. For the purpose of subgroup analysis, we defined a standard Bu-Cy regimen as a total dose of IV 12.8 and 120 mg/kg, respectively, and a standard Bu-Flu regimen as a total dose of IV 12.8 mg/kg and 150-160 mg/m 2 , respectively.
Risk of bias assessment
Trials fulfilling inclusion criteria were assessed for methodological quality by the two reviewers (SB and OC). We performed sensitivity analyses based on the risk of bias items listed below. No reporting of data in the studies was considered as a high risk for bias. Utilizing sensitivity analysis, we separately analysed the RCTs and the non-randomized trials. We extracted information regarding intention to treat analyses, sample size, reporting of exclusions after randomization and their cause. For randomized trials, we used the Cochrane Collaboration's tool for assessing risk of bias with a subjective judgment regarding protection from bias: low risk, high risk of bias or unclear risk (Cochrane handbook version 5.1.0.; available at www.cochrane-handbook.org o http://www.cochranehandbook.org4).
For prospective non-randomized studies, we used the Newcastle-Ottawa scale (http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm) to assess whether the study adjusted for the confounders listed in Table 2 . For each study, we summed up the number of the well-comparable parameters to a numeric Ottawa score, which was used to grade the quality of the study.
For all study designs, we assessed the comparability of the study groups based on these confounders: age and status of disease (CR vs persistent disease).
Data synthesis
Dichotomous data were analyzed by calculating the relative risk (RR) for each trial with its 95% confidence intervals (CIs). We analyzed continuous data by calculating weighted mean difference using the mean and SD of each trial and calculating the effect size (average mean difference) and the 95% CI, assuming comparisons made between the mean duration of symptoms in the two groups were normally distributed.
Heterogeneity and publication bias
Heterogeneity in the results of the trials was assessed by calculating a test of heterogeneity (Χ 2 and I
2
). We anticipated between-trial variation in estimation of morbidity and mortality for trials comparing patients at different risk levels, given different conditioning regimens, and using IV or oral busulfan. Subgroup analyses were performed to assess the impact of these possible sources of heterogeneity on the main results. A random effects model was used in case of significant heterogeneity (I 2 450%).
RESULTS
Our search yielded 197 potentially relevant trials of which 11 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] were considered for further investigation. Of these, five studies were excluded [13] [14] [15] [16] [17] ( Figure 1 ). In addition, 14 18-31 abstract proceedings were identified and were also considered for further investigation. Three of the abstract proceedings 23, 28, 31 were simultaneously published as a journal paper. Two others were excluded as the preparative regimens were reduced intensity and not myeloablative. 27, 30 Nine abstract proceedings were included in the systematic review.
Potentially relevant trials identified and screened for retrieval (n=197) Full text articles retrieved for more detailed evaluation (n=11) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) Non-comparative trials (n=188)
Comparative trials included in the meta-analysis (n= 15) Trials excluded (n=5): Double publication (n=3) (13, 15, 17) A significant percentage of patients received reduced intensity equivalent doses of busulfan (n=1) (14) Paucity of information on primary & secondary outcomes (n=1) (16) Publications from conference proceedings (n=9) (18) (19) (20) (21) (22) (24) (25) (26) 29) Figure 1. Table 1 depicts the studies' demographic data. Data regarding demographics, host and donor characteristics, and transplantation preparative regimens are summarized in Table 1 . The range of patients' ages in most studies was 17-59 years old. Baseline diseases in most patients were AML/MDS and matched-related donor was the most common donor type.
In patients given the Bu-Cy regimen, oral busulfan was administered in four trials 9, 12, 26, 29 at a dose of 14-16 mg/kg and IV busulfan was administered in seven trials at a dose of 12.8 mg/kg 8, 10, 11, [20] [21] [22] 24 and in one study at a dose of 9.6 mg/kg. 7 In two studies, patients were given either oral or IV busulfan at a dose of 12.8-16 mg/kg. 9, 12 In patients given the Bu-Flu regimen, IV busulfan was given in 11 trials [8] [9] [10] [11] [12] [20] [21] [22] 24, 26, 29 at a total dose of 12.8 mg/kg and in one trial at a dose of 9.6 mg/kg. 7 Cyclophosphamide was given at a total dose of 120 mg/kg in 11 trials [8] [9] [10] [11] [12] 18, 20, 22, 24, 26, 29 and 200 mg/kg in one study. 21 In one study by Liu et al., 7 the dose of cyclophosphamide was 3.6 g/m 2 . In this study, patients were also given lower doses of busulfan in addition to cytarabine and semustine in both arms.
IV fludarabine dose ranged between 125-200 mg/m 2 . None of the trials utilized busulfan pharmacokinetic drug levels for the correction of busulfan dose.
Two abstracts did not report the specific doses, however, they utilized standard myeloablative regimens 19, 25 and were included in the analysis. Acute GvHD was graded according to the 1994 Consensus Conference on Acute GvHD. Table 2 describes the assessment of risk of bias of the included trials. All the non-randomized comparative trials had a high Ottawa-Newcastle score (44).
Supplementary Table 1 depicts for each analyzed outcome, all the relevant trials that have reported the data.
Primary outcomes NRM at 100 days. At 100 days post HCT, there was a lower risk of NRM in patients given Bu-Flu regimen compared with those given Bu-Cy regimen (RR 0.56; 95% CI 0.34-0.92,1002 patients, 8 trials), Figure 2a . Sensitivity analysis including RCTs only showed similar results (RR 0.49; 95% CI 0.25-0.98). Meta-regression showed a borderline correlation between the median age of patients and the risk for NRM at 100 days (r = − 0.83, P = 0.07, 6 studies).
ACM at the end of study. There were no differences in ACM at the end of study between patients given Bu-Flu and those given Bu-Cy (RR 0.81; 95% CI 0.64-1.02, 13 trials, 1371 patients, I 2 = 60%, random effect model), Figure 2b . Sensitivity analysis including only RCTs showed similar results (RR 1.02; 95% CI 0.72-1.44, 4 trials, 591 patients, I 2 = 57%, random effect model). Subgroup analysis according to standard doses of Bu-Flu and Bu-Cy showed similar results (RR 0.91; 95% CI 0.65-1.28, 5 trials, 775 patients, I 2 = 71%, random effect model). Subgroup analysis of trials in which busulfan was administered IV showed similar results (RR 0.91; 95% CI 0.69-1.22, 6 trials, 880 patients, I 2 = 64%, random effect model). Subgroup analysis of trials in which the median patients' age was above 40 years showed also similar results (RR 0.94; 95% CI 0.73-1.22, 7 trials, 931 patients, I 2 = 63%, random effect model).
Secondary outcomes
Engraftment. There was no difference in the time to neutrophil engraftment between patients given Bu-Cy regimen and patients given Bu-Flu regimen (weighted mean difference 0.90; 95% CI 0.04-1.76, 6 trials, 516 patients, I 2 = 63%, random effect model). Heterogeneity was caused mainly because of the trial conducted by Liu et al., 7 in which patients were given lower doses of busulfan in addition to cytarabine and semustine. After eliminating this study, no heterogeneity was demonstrated (weighted mean difference 1.19; 95% CI 0.68-1.70, 5 trials, 411 patients), Supplementary Figure 1.
Primary and secondary graft failure. The risks of both primary and secondary graft failure were similar between the two regimens (RR 0.90; 95% CI 0.33-2.50, 7 trials, 652 patients and RR 2.94; 95% CI 0.68-12.74, 3 trials, 275 patients, respectively). Sensitivity analysis including only RCTs showed similar results, Supplementary Figures  2 and 3 . Of note, one of the studies reported on 4 out of 62 patients in the Bu-Flu arm that had a secondary graft failure (compared with none in the Bu-Cy arm). 8 Three of the four secondary graft failures occurred approximately at day 110 post HCT. Two of the four patients had myelodysplastic syndrome and were treatment naive. Busulfan fludarabine for allogeneic HCT: a meta-analysis S Ben-Barouch et al ACM at 100 days There was no difference in the the risk of ACM at 100 days between patients given Bu-Flu and those given Bu-Cy (RR 0.85; 95% CI 0.56-1.30, 9 trials, 843 patients, I 2 = 0%), Supplementary  Figure 9 . Sensitivity analysis including only RCTs showed similar results (RR 0.94; 95% CI 0.43-2.06, 3 trials, 339 patients, I 2 = 0%). Subgroup analysis according to standard doses of Bu-Flu and Bu-Cy showed similar results (RR 0.87; 95% CI 0.51-1.48, 4 trials, 511 patients). Subgroup analysis of trials in which busulfan was administered IV showed similar results (RR 1.03; 95% CI 0.61-1.73, 5 trials, 589 patients, I 2 = 64%, random effect model). Subgroup analysis of trials in which the median patients' age was above 40 years showed also similar results (RR 0.86; 95% CI 0.52-1.44, 4 trials, 458 patients, I 2 = 63%, random effect model).
Transplantation-related toxicity
Relapse rate There was no difference in the risk of relapse between the two groups (RR 0.84; 95% CI 0.71-1.00, 1079 patients, 11 trial). Sensitivity analysis including only RCTs showed a similar risk of relapse between the two groups (RR 0.95; 95% CI 0.63-1.44, 591 patients, 4 trials, Random effects model, I 2 = 54%), Figure 3c . Subgroup analysis according to trials with 420% of the patients having a high-risk disease of relapse showed a similar risk of relapse between the two groups (RR 1.02; 95% CI 0.82-1.27, 365 patients, 3 trials).
DISCUSSION
Our systematic review, which compiled all comparative studies comparing Bu-Cy and Bu-Flu as preparative regimen for patients given allografts, yielded two main clinically significant results: the first is that Bu-Flu is associated with a lower risk for early NRM and the second is the similar efficacy of the two regimens.
This meta-analysis shows no difference in ACM at 100 days and at the end of study between the two groups. This was true also in a sensitivity analysis incorporating only RCTs. These findings support previous studies that suggested that the incorporation of Bu-Flu regimen results in a favorable balance between antimalignancy effect and reduced toxicity and align with a recent large retrospective analysis of the International Bone Marrow Transplant Registry data that showed similar ACM between the two groups (P = 0.63). 33 Focusing on the toxicity profile of both regimens, Bu-Flu has been traditionally considered less toxic than the standard Bu-Cy regimen. 34 In our analysis, we focused on four domains associated with the toxicity profile. First, we showed that the risk of mucositis grade 3-4 was similar between the two regimens. The similar risk may be explained by several ways: (1) different scales were used in the different trials for mucositis grading; (2) severity of mucositis may result from both the preparative regimen, and the GvHD prophylaxis protocol. 35 Second, although supported by only 2 RCTs, the risk of microbiologically documented infections was lower in patients given Bu-Flu, compared with those given Bu-Cy, similar to data published in other clinical scenarios. 36 Third, we found that there was a lower risk of SOS in patients given Bu-Flu compared with those given Bu-Cy; however, this was no longer true in sensitivity analysis including only RCTs. The additive cytotoxic effect of both cyclophosphamide and busulfan through depletion of hepatic glutathione results in serious liver toxicity and subsequently with an increased risk of SOS. Unlike cyclophosphamide, fludarabine is mainly metabolized via glutathione-independent pathways and, thus, does not increase the toxicity profile of busulfan. 34 Our sensitivity analysis shows similar risk of SOS between the two groups. This may stem from a sample size issue (the trend of the risk ratio aligns in the same direction with the overall analysis); however, taking into consideration all RCTs incorporated IV and not PO busulfan, this finding may be secondary to the safer profile of IV busulfan as previously shown. 33 Fourth and most importantly, we found that the risk of NRM at 100 days was lower in patients given Bu-Flu compared with those given Bu-Cy; however, this did not affect the overall NRM at the end of study period. We hypothesize that the lower early NRM in patients given Bu-Flu reflects the overall lower risk of early toxicities in patients given this regimen, as previously shown by others. 33, 37, 38 A meta regression according to patients' age supported these findings showing the correlation between elderly patients and superiority of the Bu-Flu regimen in terms of the risk of NRM. Of note, NRM at the end of follow-up was similar between the two groups. We hypothesize that this may stem from the similar risks of grade 3-4 acute GvHD and extensive chronic GvHD. Presumably the overall similarity in the NRM at the end of follow-up combined with the similar risk for relapse, translated into comparable ACM.
Several limitations in our analysis merit consideration. First, the paucity of RCTs promoted us to incorporate non-randomized comparative trials to the meta-analysis. To control for this limitation, when possible, we performed sensitivity analysis including only RCTs. Furthermore, most comparisons were not statistically heterogeneous, which may support the hypothesis that the nonrandomized comparative studies did not introduce significant bias. Nevertheless, when discussing and summarizing our results, we highlighted the conclusions in which the RCTs sensitivity analyses supported the overall analyses. Still, considering a meta-analysis of RCTs as the gold standard of evidence based medicine, the robustness of our results may be hampered by the small number of RCTs. Nine of the trials were published only as conference proceedings and not as peer reviewed articles; thus, the report of these studies' quality and results is incomplete.
In conclusion, our systematic review and meta-analysis shows that Flu-Bu is not inferior to Bu-Cy as a myeloablative preparative regimen in patients given allografts and may be associated with a lower early NRM. Thus, elderly patients and those who are more susceptible to regimen-related toxicities may benefit from Bu-Flu. Additional well-controlled randomized trials that will further assess the Bu-Flu regimen among specific subgroups of patients' populations are needed.
